Saurabh Mukherjea’s debut book ‘Gurus of Chaos’ has all the ingredients necessary to put us on the right path to finding winning stocks. We learn from the failures and successes of top fund managers and understand how our attitudinal deficiencies are hindering our progress from becoming successful investors
Anmol Ganjoo, Vp-Institutional Equities of JM Financial, has explained why he is bullish on specific Pharma stocks
Microsec enjoys an excellent reputation for finding winning stocks. They have now put the spotlight on 9 stocks, of which 6 have been rated a “Strong Buy”
Daljeet Kohli of IndiaNivesh is acknowledged as an authority on the Pharma sector. He understands the sector very well and knows what makes each stock tick. His latest stock recommendations require to be paid attention to by us
Daljeet Kohli applied an elementary investing rule while recommending a buy of Infosys. He has taken home huge annualized gains of 120% for his efforts. There is much that we can and should learn from this episode
Saurabh Mukherjea, Stock Wizard with Ambit Capital, has announced Century Ply as his latest stock pick. We need to pay attention and pocket the stock before the savvy investors do
Daljeet Kohli’s Model Portfolios have heavily outperformed the Benchmark BSE 500 Index. The Portfolios have now been recast with several additions & deletions
Shilpa Medicare’s Q1FY15 results sent a chill down the spine of its shareholders and their knee-jerk reaction was to dump the stock, sending it reeling down 10%. However, if you peer closely at the results, you will realize that it is an aberration and an opportunity to tuck into the stock says Daljeet Kohli
Sanjoy Bhattacharyya is rarely exuberant about a stock. This time, he has made an exception and come out with all guns blazing. He says we have a “great chance” to buy a “wonderfully run company, with a tremendous track record and high quality management”. Can we afford to miss the opportunity to grab this stock?
IPCA is reeling under the FDA related bad news. However, as there is no doubting its status as a powerhouse stock, is this the time to be a contrarian and tuck into the stock? Saurabh Mukherjea of Ambit considers the issue and gives valuable advice
Recent Comments